<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00000669</url>
  </required_header>
  <id_info>
    <org_study_id>ACTG 091</org_study_id>
    <secondary_id>070V1</secondary_id>
    <secondary_id>AI454-003</secondary_id>
    <nct_id>NCT00000669</nct_id>
  </id_info>
  <brief_title>A Phase I Safety and Pharmacokinetics Study of 2',3'-Dideoxyinosine (ddI) Administered Twice Daily to Infants and Children With AIDS or Symptomatic HIV Infection</brief_title>
  <official_title>A Phase I Safety and Pharmacokinetics Study of 2',3'-Dideoxyinosine (ddI) Administered Twice Daily to Infants and Children With AIDS or Symptomatic HIV Infection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute of Allergy and Infectious Diseases (NIAID)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>National Institute of Allergy and Infectious Diseases (NIAID)</source>
  <brief_summary>
    <textblock>
      To determine the safety and maximum tolerated dose (MTD) of 2',3'-dideoxyinosine (ddI), given&#xD;
      orally and intravenously, in infants and children with AIDS. The study also measures&#xD;
      bloodstream and cerebrospinal fluid (CSF) levels of the administered drug, and provides a&#xD;
      preliminary assessment of the effectiveness of ddI on HIV replication.&#xD;
&#xD;
      AMENDED: Based on safety established in the first dosing phase of 52 weeks and long term&#xD;
      dosing data in adults, the dosing period will be extended to 104 weeks. Original design:&#xD;
      Information presently available indicates that ddI has high antiviral activity with less&#xD;
      apparent toxicity than zidovudine (AZT) (the drug presently used to treat AIDS).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      AMENDED: Based on safety established in the first dosing phase of 52 weeks and long term&#xD;
      dosing data in adults, the dosing period will be extended to 104 weeks. Original design:&#xD;
      Information presently available indicates that ddI has high antiviral activity with less&#xD;
      apparent toxicity than zidovudine (AZT) (the drug presently used to treat AIDS).&#xD;
&#xD;
      AMENDED: Dosing will proceed for 104 weeks at each dose level. Original design: Five patients&#xD;
      are treated at the initial dose level. Because ddI is not stable in the acid environment of&#xD;
      the stomach, oral doses of ddI follow administration of an antacid. An alternative method of&#xD;
      dosing is to mix the reconstituted ddI with an appropriate volume of Maalox TC or Mylanta II.&#xD;
      In order to determine the MTD, successive groups of 5 patients enter the study at a higher&#xD;
      dose level after 3 patients have experienced 3 weeks of dosing and significant toxicities&#xD;
      have not developed. Patients are assigned to treatment groups in the order in which they are&#xD;
      enrolled. Dosing proceeds for 16 weeks at each dose level. However, consideration is given to&#xD;
      escalating patients entered at the lowest dose to the next dose level after 10 weeks of&#xD;
      dosing. The dose escalation continues until toxicities requiring dose modifications are found&#xD;
      in 2 of 5 in any group.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <enrollment>25</enrollment>
  <condition>HIV Infections</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Didanosine</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria&#xD;
&#xD;
        Concurrent Medication:&#xD;
&#xD;
        Allowed:&#xD;
&#xD;
          -  Aerosolized pentamidine for Pneumocystis carinii pneumonia (PCP) prophylaxis if this&#xD;
             drug is extended to children.&#xD;
&#xD;
          -  Acute therapy not exceeding 7 days with oral or intravenous acyclovir for herpes&#xD;
             simplex infections.&#xD;
&#xD;
          -  Trimethoprim / sulfamethoxazole for Pneumocystis carinii infections during course of&#xD;
             study at discretion of investigator after discussion with the sponsor.&#xD;
&#xD;
          -  Symptomatic therapy with analgesics, antihistamines, antiemetics, antidiarrheal&#xD;
             agents, or other supportive therapy as deemed necessary by the principal investigator.&#xD;
&#xD;
        Patients must have:&#xD;
&#xD;
          -  Diagnosis of AIDS as defined by CDC or meeting CDC P2 classification.&#xD;
&#xD;
          -  Patients must be free of opportunistic infection or other serious bacterial, fungal,&#xD;
             or parasitic infection at time of entry into study.&#xD;
&#xD;
          -  Life expectancy &gt; 6 months.&#xD;
&#xD;
          -  Parent or guardian (and patient as applicable) able to give informed consent.&#xD;
&#xD;
          -  Available for follow-up for at least 6 months.&#xD;
&#xD;
          -  Allowed: Hemophilia.&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
        Co-existing Condition:&#xD;
&#xD;
        Children with the following are excluded:&#xD;
&#xD;
          -  Chronic hematologic disorders unrelated to coagulation defects, hemoglobinopathies, or&#xD;
             ITP.&#xD;
&#xD;
          -  Intractable diarrhea.&#xD;
&#xD;
          -  No venous access.&#xD;
&#xD;
          -  History of seizures within previous 2 years or currently requiring anticonvulsants for&#xD;
             control.&#xD;
&#xD;
          -  Currently active heart disease as evidenced by a cardiac arrhythmia or other&#xD;
             significant abnormality on routine electrocardiography (ECG) or shortening fraction of&#xD;
             &lt; 10 percent on echocardiogram.&#xD;
&#xD;
          -  Renal disease.&#xD;
&#xD;
          -  Any other clinical condition that in the opinion of the investigator makes the patient&#xD;
             unsuitable for study.&#xD;
&#xD;
        Concurrent Medication:&#xD;
&#xD;
        Excluded:&#xD;
&#xD;
          -  Antiretroviral drugs.&#xD;
&#xD;
          -  Zidovudine (AZT).&#xD;
&#xD;
          -  AL 721.&#xD;
&#xD;
          -  Interferon.&#xD;
&#xD;
          -  Corticosteroids.&#xD;
&#xD;
          -  Immunomodulating drugs.&#xD;
&#xD;
          -  Other systemic investigation agent.&#xD;
&#xD;
          -  Ribavirin.&#xD;
&#xD;
          -  Rifampin, barbiturates, or any other potent inducer or inhibitor of drug-metabolizing&#xD;
             enzymes.&#xD;
&#xD;
          -  Cytotoxic anticancer therapy.&#xD;
&#xD;
          -  H-2 blockers.&#xD;
&#xD;
          -  Intravenous ketoconazole.&#xD;
&#xD;
          -  Immunoglobulin preparations.&#xD;
&#xD;
        Children with the following are excluded:&#xD;
&#xD;
          -  Chronic hematologic disorders unrelated to coagulation defects, hemoglobinopathies, or&#xD;
             ITP.&#xD;
&#xD;
          -  Intractable diarrhea.&#xD;
&#xD;
          -  No venous access.&#xD;
&#xD;
          -  History of seizures within previous 2 years or currently requiring anticonvulsants for&#xD;
             control.&#xD;
&#xD;
          -  Currently active heart disease as evidenced by a cardiac arrhythmia or other&#xD;
             significant abnormality on routine electrocardiography (ECG) or shortening fraction of&#xD;
             &lt; 10 percent on echocardiogram.&#xD;
&#xD;
          -  Renal disease.&#xD;
&#xD;
          -  Any other clinical condition that in the opinion of the investigator makes the patient&#xD;
             unsuitable for study.&#xD;
&#xD;
          -  Renal disease.&#xD;
&#xD;
        Prior Medication:&#xD;
&#xD;
        Excluded:&#xD;
&#xD;
          -  Any prior therapy which in the opinion of the investigator would make the patient&#xD;
             unsuitable for study.&#xD;
&#xD;
        Excluded within 2 weeks of study entry:&#xD;
&#xD;
          -  Trimethoprim / sulfamethoxazole.&#xD;
&#xD;
        Excluded within 1 month of study entry:&#xD;
&#xD;
          -  Study drug or other antiretroviral drug or systemic investigational agent.&#xD;
&#xD;
          -  Any agent known as a potent inducer or inhibitor of drug metabolizing enzymes.&#xD;
&#xD;
          -  H-2 blockers.&#xD;
&#xD;
          -  Ketoconazole.&#xD;
&#xD;
          -  Immunoglobulin preparations.&#xD;
&#xD;
        Excluded within 3 months of study entry:&#xD;
&#xD;
          -  Ribavirin.&#xD;
&#xD;
        Excluded:&#xD;
&#xD;
          -  Zidovudine (AZT) for &gt; 6 months.&#xD;
&#xD;
          -  Cytotoxic anticancer therapy.&#xD;
&#xD;
        Prior Treatment:&#xD;
&#xD;
        Excluded within 4 weeks of study entry:&#xD;
&#xD;
          -  Blood transfusion.&#xD;
&#xD;
          -  Lymphocyte transfusions for immune reconstitution.&#xD;
&#xD;
          -  Bone marrow transplant.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>3 Months</minimum_age>
    <maximum_age>12 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Scott GB</last_name>
    <role>Study Chair</role>
  </overall_official>
  <location>
    <facility>
      <name>Univ of Alabama at Birmingham</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Univ of Miami School of Medicine</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>331361013</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Regional Medical Ctr, Memphis</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38105</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baylor College of Medicine</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Univ TX Health Science Ctr</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Butler KM, Husson RN, Balis FM, Brouwers P, Eddy J, el-Amin D, Gress J, Hawkins M, Jarosinski P, Moss H, et al. Dideoxyinosine in children with symptomatic human immunodeficiency virus infection. N Engl J Med. 1991 Jan 17;324(3):137-44. doi: 10.1056/NEJM199101173240301.</citation>
    <PMID>1670591</PMID>
  </reference>
  <verification_date>October 1996</verification_date>
  <study_first_submitted>November 2, 1999</study_first_submitted>
  <study_first_submitted_qc>August 30, 2001</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 31, 2001</study_first_posted>
  <last_update_submitted>August 25, 2008</last_update_submitted>
  <last_update_submitted_qc>August 25, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 26, 2008</last_update_posted>
  <keyword>Didanosine</keyword>
  <keyword>Drug Evaluation</keyword>
  <keyword>Acquired Immunodeficiency Syndrome</keyword>
  <keyword>AIDS-Related Complex</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infections</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>HIV Infections</mesh_term>
    <mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Didanosine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

